PMID- 37916337
OWN - NLM
STAT- MEDLINE
DCOM- 20231103
LR  - 20231103
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 27
IP  - 20
DP  - 2023 Oct
TI  - Analysis of the efficacy of azelastine nasal spray combined with mussel mucin in 
      the treatment of allergic rhinitis and the influence of peripheral blood CCL26 
      and CCR3 levels.
PG  - 9738-9746
LID - 34145 [pii]
LID - 10.26355/eurrev_202310_34145 [doi]
AB  - OBJECTIVE: A retrospective study was conducted to investigate the efficacy of 
      azelastine nasal spray combined with mussel mucin in the treatment of allergic 
      rhinitis (AR) and the effects of CCL26 and CC chemokine receptor-3 (CCR3). 
      PATIENTS AND METHODS: A total of 80 patients with AR admitted to our hospital 
      from March 2020 to March 2022 were included as the research objects. All subjects 
      were divided into two groups according to the different therapeutic strategies by 
      reviewing the patient's treatment. The control group (n = 40) was given 
      azelastine nasal spray, while the study group (n = 40) was treated with a 
      combination of mussel mucin and azelastine nasal spray. The clinical efficacy, 
      clinical symptoms, and sleep quality improvement of the two groups were 
      calculated and compared retrospectively. The serological indexes were compared, 
      and the incidence of adverse reactions between the two groups was calculated 
      retrospectively based on the patient's medical records. RESULTS: In the study and 
      control groups, the effective rate was 95.00% and 72.50%. After treatment, the 
      symptom scores of nasal congestions, nasal itching, sneezing, and runny nose and 
      the total score of Pittsburgh sleep quality index (PSQI) in the study group were 
      remarkably less. After treatment, the serum levels of sVCAM-1, interleukin-4 
      (IL-4), and immunoglobulin E (IgE) were decreased, and the levels of IL-12 were 
      upregulated. Following treatment, Minimum nasal cross-section (NMCA) and total 
      nasal resistance (TNR) at 75Pa in the study group were reduced more noticeably (p 
      < 0.05). After treatment, the expression levels of CCL26 and CCR3 in peripheral 
      blood were significantly decreased. In the control and study groups, the 
      incidence of adverse reactions was 7.50% and 10.00%. CONCLUSIONS: Azelastine 
      nasal spray combined with mussel mucin is effective in the treatment of allergic 
      rhinitis, which can effectively improve patients' clinical symptoms, alleviate 
      nasal ventilation disorders, reduce inflammatory reactions, and improve sleep 
      quality. This strategy of combined treatment is safe and, therefore, worth 
      advocating.
FAU - Liu, Y
AU  - Liu Y
AD  - Department of Health Medicine, The Sixth Medical Center of PLA General Hospital, 
      Beijing, China. zgm65811@sina.com.
FAU - Liu, S
AU  - Liu S
FAU - Lu, S-F
AU  - Lu SF
FAU - Zang, G-M
AU  - Zang GM
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Nasal Sprays)
RN  - ZQI909440X (azelastine)
RN  - 0 (Mucins)
RN  - 0 (CCL26 protein, human)
RN  - 0 (Chemokine CCL26)
RN  - 0 (CCR3 protein, human)
RN  - 0 (Receptors, CCR3)
SB  - IM
MH  - Humans
MH  - Nasal Sprays
MH  - Retrospective Studies
MH  - Mucins/therapeutic use
MH  - *Rhinitis, Allergic, Seasonal
MH  - Administration, Intranasal
MH  - *Rhinitis, Allergic/drug therapy
MH  - Double-Blind Method
MH  - Chemokine CCL26
MH  - Receptors, CCR3
EDAT- 2023/11/02 06:42
MHDA- 2023/11/03 06:44
CRDT- 2023/11/02 04:43
PHST- 2023/11/03 06:44 [medline]
PHST- 2023/11/02 06:42 [pubmed]
PHST- 2023/11/02 04:43 [entrez]
AID - 34145 [pii]
AID - 10.26355/eurrev_202310_34145 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2023 Oct;27(20):9738-9746. doi: 
      10.26355/eurrev_202310_34145.